Trifluoperazine ( DrugBank: Trifluoperazine )
2 diseases
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 283 | 後天性赤芽球癆 | 1 |
| 284 | ダイアモンド・ブラックファン貧血 | 1 |
283. 後天性赤芽球癆
臨床試験数 : 19 / 薬物数 : 36 - (DrugBank : 23) / 標的遺伝子数 : 20 - 標的パスウェイ数 : 102
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03966053 (ClinicalTrials.gov) | September 13, 2019 | 23/5/2019 | The Use of Trifluoperazine in Transfusion Dependent DBA | Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia | Diamond Blackfan Anemia;Pure Red Cell Aplasia | Drug: Trifluoperazine | Adrianna Vlachos | NULL | Terminated | 18 Years | 65 Years | All | 2 | Phase 1/Phase 2 | United States |
284. ダイアモンド・ブラックファン貧血
臨床試験数 : 36 / 薬物数 : 95 - (DrugBank : 34) / 標的遺伝子数 : 23 - 標的パスウェイ数 : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03966053 (ClinicalTrials.gov) | September 13, 2019 | 23/5/2019 | The Use of Trifluoperazine in Transfusion Dependent DBA | Phase I/II, Open Label Study to Determine Safety of Trifluoperazine (TFP) in Adults With Red Blood Cell Transfusion-Dependent Diamond Blackfan Anemia | Diamond Blackfan Anemia;Pure Red Cell Aplasia | Drug: Trifluoperazine | Adrianna Vlachos | NULL | Terminated | 18 Years | 65 Years | All | 2 | Phase 1/Phase 2 | United States |